Last reviewed · How we verify
An Open-Label, Multicentre, Randomised, Phase III Study Comparing Topotecan/Cisplatin and Topotecan/Etoposide Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer
Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer
Details
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 700 |
| Start date | 2002-08 |
| Completion | 2007-02 |
Conditions
- Lung Cancer, Small Cell
Interventions
- Intravenous topotecan/cisplatin
- Intravenous etoposide/cisplatin
Primary outcomes
- Median overall survival time of participants — Up to 1 year after randomization of the last patient
Countries
Austria, Germany